Subscribe to our Newsletters !!
Out there, in the fossil beds of Illinois, imposin
Realizing that contamination risks made 70% of rec
This doesn't feel like another one of my English e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referre
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers,Welcome to the latest issue of The Magazine
The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB’s leading in vitro lung simulation tool DissolvIt®.
DissolvIt® has been increasingly recognized in the inhalation industry as a leading solution for generating “IVIVC” data – that is in vitro dissolution and absorption data early on in the drug development process that closely predicts later-stage in vivo data. Such data can significantly reduce risk and costs early on in drug development.
ISAB’s contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.39 million SEK (130K Euros) with a US respiratory pharmaceutical company. The new client has chosen ISAB’s unique in vitro lung simulation tool DissolvIt® for its project.
With a growing body of publications like “In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models” (Journal of Aerosol Science 2021) there is increasing interest in DissolvIt’s advanced capabilities.
ISAB CEO Manoush Masarrat: “We are very pleased to be working with this new US client. This clearly demonstrates the client’s confidence in our world-class expertise, and the leading in vitro capabilities of DissolvIt®. We are delighted to carry out this research and look forward to this exciting collaboration.”
